Login to Your Account



BioCryst, Presidio 'Nuc' Tie; Plans Flu HAE but Fell Far

By Randy Osborne
Staff Writer

Friday, November 30, 2012
Investors must wait until a conference call for full details, but the decision by BioCryst Pharmaceuticals Inc. and Presidio Pharmaceuticals Inc. to ditch their $101 million merger might seem almost inevitable, coming in the wake of problems for BioCryst's drug candidates in flu, hepatitis C virus and hereditary angioedema.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription